Shire plc, the global specialty biopharmaceutical company, announced that the United States District Court for the District of Columbia, following extensive briefing by the parties and an oral hearing, has upheld the decision of the US Food and Drug Administration (US FDA) to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate—currently marketed by Shire US Inc ...
Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate ...

Aviva, Michael Page, Shire, WPP: UK, Irish Equity Preview
Bloomberg
... Columbia has upheld the decision of the US Food and Drug Administration to grant five years of exclusivity to attention-deficit disorder drug Vyvanse. ...

and more »
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by ...

Hardy, Michael Page, Shire, WPP: UK, Irish Equity Preview
Bloomberg
... Columbia has upheld the decision of the US Food and Drug Administration to grant five years of exclusivity to attention-deficit disorder drug Vyvanse. ...

and more »